Successful Nobel Biocare Global Symposium held in New York

6 July 2010, 07:00 CET

From 24 to 27 June 2010, Nobel Biocare held a Global Symposium dedicated to the promotion of innovative and scientifically proven solutions in dentistry. This exclusive three-day event brought together 1,500 world-renowned dental professionals from 46 countries. The symposium featured clinical treatment concepts, clinical applications, emerging technologies and advanced treatment planning. There was also a post symposium on fully edentulous solutions. This Global Symposium was the first in a series of similar events to be held in Asia and Europe.

Building on its more than 45-year heritage of science-based innovations, Nobel Biocare is organizing a series of symposia for 2010 that will allow dental professionals from around the world to exchange their latest know-how and professional experiences. The Global Symposium in New York marks the beginning of this series. The program for the symposium was developed by an independent scientific committee chaired by Dr Jonathan Ferencz, Clinical Professor at New York University’s College of Dentistry. The symposium focused on key topics such as immediate function, the contribution of emerging technologies to prosthetic success, optimization of soft tissue health outcomes to enhance long-term predictability, possibilities for fully edentulous treatments, advanced treatment planning and maxillofacial concepts. The program was accompanied by a broad array of educational seminars, hands-on training sessions and a post-symposium event on fully edentulous solutions including zygomatic implants.

Dr Jonathan Ferencz, Chairman of the Scientific Committee, said: “With this program, we wanted to highlight the patient benefits of the latest treatment modalities. Thanks to the vast concentration of expert dental knowledge and insight and the high quality of the opinion leaders in attendance, I am confident that we delivered a unique symposium of great academic and practical value and relevance to the participants. The Scientific Committee is very pleased with the outcome of the symposium.”

Domenico Scala, CEO of Nobel Biocare: “We are very pleased with the high quality the symposium offered and the fact that it attracted both existing and new customers. The large attendance and great interest attest to the fact that the treatment modalities discussed by the best dental experts in the industry are of great relevance to dental professionals. We are very fortunate that we could call on such a prestigious group of opinion leaders to share their expertise in an atmosphere of partnership and cooperation.”

The next Global Symposium will take place in Tokyo, Japan, in August 2010. Further regional/local symposia will be held in London, Stockholm, Zurich, Berlin, Barcelona, Rimini and Moscow during the second half of the year.

Details on upcoming Nobel Biocare events can be found online at:
www.nobelbiocare.com/events 
 

Media contact

Name: Nicolas Weidmann (Senior Vice President Communications)
Tel: +41 43 211 42 80; +41 79 372 29 81
E-mail: nicolas.weidmann@nobelbiocare.com

Investor contact

Name: Süha Demokan (Head of Investor Relations)
Tel: +41 43 211 42 30; +41 79 430 81 46
E-mail: suha.demokan@nobelbiocare.com

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to completely edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace®), individualized prosthetics and equipment (NobelProcera™), guided surgery solutions and biomaterials. Nobel Biocare has over 2,400 employees and recorded revenue of EUR 569.2 million in 2011. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.

Disclaimer
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Media contact

N Weidmann

Nicolas Weidmann

Senior Vice President Communications

Nobel Biocare Management AG
P.O. Box
CH - 8058 Zurich-Airport
Switzerland

+41 43 211 42 80

+41 79 372 29 81

+41 43 211 42 42

Give us your feedback!

Summarize your comments
Email